Jake R Morgan1, Emily K Quinn2, Christine E Chaisson3, Elizabeth Ciemins4, Nikita Stempniewicz4, Laura F White5, Marc R Larochelle6. 1. Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA, USA; OptumLabs Visiting Scholar, OptumLabs, Eden Prairie, MN, USA. Electronic address: jakem@bu.edu. 2. Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, USA. 3. OptumLabs, Eden Prairie, MN, USA. 4. American Medical Group Association, Alexandria, VA, USA. 5. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 6. Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.
Abstract
INTRODUCTION: Medications for opioid use disorder (MOUD) are highly effective, but barriers along the cascade of care for opioid use disorder (OUD) from diagnosis to treatment limit their reach. For individuals desiring MOUD, the final step in the cascade is filling a written prescription, and fill rates have not been described. METHODS: We used data from a large de-identified database linking individuals' electronic medical records (EMR) and administrative claims data and employed a previously developed algorithm to identify individuals with a new diagnosis of OUD. We included individuals with a prescription for buprenorphine or naltrexone recorded in the EMR. The outcome was a prescription fill within 30 days as reported in claims data. We compared demographic and clinical characteristics between those who did and did not fill the prescription and used a Kaplan-Meier curve to assess whether fill rates differed based on patient copay. RESULTS: We identified 264 individuals with a new diagnosis of OUD who had a prescription written for buprenorphine or oral naltrexone. Of these, 70% (184) filled the prescription within 30 days, and more than half (57%) filled the prescription on the day it was written. Individuals with prescription copay at or below the mean had a 75% fill rate at 30 days compared with 63% for those with copay above the mean (p < 0.05) and this difference was consistent across fill times (log rank p-value <0.05). CONCLUSIONS: It is alarming that nearly 1 in 3 MOUD prescriptions go unfilled. More research is needed to understand and reduce barriers to this final step of the OUD cascade of care.
INTRODUCTION: Medications for opioid use disorder (MOUD) are highly effective, but barriers along the cascade of care for opioid use disorder (OUD) from diagnosis to treatment limit their reach. For individuals desiring MOUD, the final step in the cascade is filling a written prescription, and fill rates have not been described. METHODS: We used data from a large de-identified database linking individuals' electronic medical records (EMR) and administrative claims data and employed a previously developed algorithm to identify individuals with a new diagnosis of OUD. We included individuals with a prescription for buprenorphine or naltrexone recorded in the EMR. The outcome was a prescription fill within 30 days as reported in claims data. We compared demographic and clinical characteristics between those who did and did not fill the prescription and used a Kaplan-Meier curve to assess whether fill rates differed based on patient copay. RESULTS: We identified 264 individuals with a new diagnosis of OUD who had a prescription written for buprenorphine or oral naltrexone. Of these, 70% (184) filled the prescription within 30 days, and more than half (57%) filled the prescription on the day it was written. Individuals with prescription copay at or below the mean had a 75% fill rate at 30 days compared with 63% for those with copay above the mean (p < 0.05) and this difference was consistent across fill times (log rank p-value <0.05). CONCLUSIONS: It is alarming that nearly 1 in 3 MOUD prescriptions go unfilled. More research is needed to understand and reduce barriers to this final step of the OUD cascade of care.
Authors: Meera Viswanathan; Carol E Golin; Christine D Jones; Mahima Ashok; Susan J Blalock; Roberta C M Wines; Emmanuel J L Coker-Schwimmer; David L Rosen; Priyanka Sista; Kathleen N Lohr Journal: Ann Intern Med Date: 2012-12-04 Impact factor: 25.391
Authors: Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson Journal: Am J Drug Alcohol Abuse Date: 2019-01-24 Impact factor: 3.829
Authors: Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi Journal: JAMA Netw Open Date: 2020-02-05
Authors: Neeraj Sood; Timothy Juday; Jacqueline Vanderpuye-Orgle; Lisa Rosenblatt; John A Romley; Desi Peneva; Dana P Goldman Journal: Health Aff (Millwood) Date: 2014-03 Impact factor: 6.301
Authors: Lucas G Hill; Lindsey J Loera; Kirk E Evoy; Mandy L Renfro; Sorina B Torrez; Claire M Zagorski; Joshua C Perez; Shaun M Jones; Kelly R Reveles Journal: Addiction Date: 2020-11-22 Impact factor: 6.526
Authors: Jake R Morgan; Bruce R Schackman; Zoe M Weinstein; Alexander Y Walley; Benjamin P Linas Journal: Drug Alcohol Depend Date: 2019-05-03 Impact factor: 4.852
Authors: Carl G Streed; Jake R Morgan; Mam Jarra Gai; Marc R Larochelle; Michael K Paasche-Orlow; Jessica L Taylor Journal: JAMA Netw Open Date: 2022-07-01